“…Ledipasvir/sofosbuvir has been approved for the treatment of HCV genotypes 1, 4, 5, and 6 across many countries globally, and its efficacy and safety in these genotypes have been reported in both clinical and real‐world studies. The SVR12 of LDV/SOF in HCV genotype 1 ranges from 95% to 98% in global clinical trials and 94% to 100% in real‐world cohorts; 13 in Asian patients with HCV genotype 1 infection, LDV/SOF has even higher SVR12 rates, with up to 97–100% in clinical trials and real‐world experience 14–17 . In HCV genotypes 4, 5, and 6, LDV/SOF has been shown to have SVR12 rates of 93–95% 18,19 …”